Beta-Blocker Therapy

Introduction to Beta-Blockers

The American Heart Association recommends beta-blockers as a treatment option for cardiovascular conditions, including heart failure, with agents such as bisoprolol, carvedilol, and metoprolol approved in the United States 1

The American College of Cardiology recommends the use of high β1-selective agents, such as bisoprolol or metoprolol, in patients with hypertension and COPD, targeting a heart rate of 60-70 beats/min 2
The European Society of Cardiology suggests that vasodilating agents, such as carvedilol or nebivolol, are preferred over traditional beta-blockers in patients with hypertension and diabetes due to their more favorable metabolic profile 3
The American Diabetes Association recommends that patients with hypertension and diabetes be treated with vasodilating beta-blockers, such as carvedilol, which may have superior glycemic control effects compared to metoprolol 3

The American College of Obstetricians and Gynecologists considers metoprolol and labetalol to be safe for use during pregnancy 4, 5
The European Respiratory Society notes that cardioselective beta-blockers, such as bisoprolol and metoprolol, are safe and reduce mortality in patients with COPD 2

The American Heart Association warns that non-selective beta-blockers can cause more bronchoconstriction and vasoconstriction than selective agents and should be avoided in patients with asthma, and are associated with an increased risk of new-onset diabetes and unfavorable lipid changes 4
The European Society of Cardiology advises against the use of atenolol as a first-line treatment due to its inferior outcomes in major trials despite its β1-selectivity 4

The American Heart Association recommends carvedilol for patients with diabetes or metabolic syndrome due to its superior glycemic control effects compared to metoprolol 6

For heart failure with reduced ejection fraction, the American College of Cardiology recommends using only carvedilol, metoprolol succinate, or bisoprolol as these are the only agents proven to reduce mortality 6, 7
For post-myocardial infarction patients, the European Society of Cardiology suggests beta-blockers should be continued for 3 years minimum in those with normal left ventricular function 6, 8

For patients with COPD, the American Thoracic Society recommends cardioselective agents (bisoprolol or metoprolol) as they are not only safe but reduce mortality and COPD exacerbations 6

The American College of Cardiology recommends high β1-selective agents (bisoprolol or metoprolol) targeting heart rates of 60-70 beats/min when beta-blockers are indicated for hypertension with comorbidities, with a preference for bisoprolol, carvedilol, and metoprolol succinate in heart failure with reduced ejection fraction due to their mortality-proven benefits 9

For heart failure with reduced ejection fraction, bisoprolol, carvedilol, and metoprolol succinate are the only beta-blockers with Class I, Level A recommendations, reducing all-cause mortality by 30-34% 9
The American Heart Association recommends targeting resting heart rates of 55-60 beats per minute in heart failure patients, with beta-blockers being a crucial component of this strategy 9
Nebivolol showed only modest benefits in elderly heart failure patients and did not reduce mortality alone, with a 14% reduction in the composite endpoint of death or cardiovascular hospitalization in the SENIORS trial 9

Symptomatic bradycardia (heart rate <50 bpm with symptoms) or heart block without a pacemaker are contraindications for beta-blocker use, according to the European Heart Journal 10
Asymptomatic bradycardia is not a contraindication, but rather an expected and beneficial effect of beta-blocker therapy, with guidelines recommending reducing doses of other heart rate-lowering drugs first, and only reducing beta-blocker doses if clearly necessary 10

The European Heart Journal recommends checking for other heart rate-lowering medications (diltiazem, verapamil, digoxin, ivabradine) and reducing or discontinuing other chronotropic drugs first if bradycardia develops, with beta-blocker dose reduction only if symptomatic bradycardia persists 10
Target heart rates should be monitored and adjusted accordingly, with a target heart rate of 55-60 bpm in heart failure patients and 60-70 bpm in hypertension with COPD, and symptomatic hypotension or heart rate <50 bpm with symptoms requiring dose adjustment 11